Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Robert Wheeler

Critical Care Medicine Lima, OH Medical Doctor

NPI 1659365740 CMS profile 346919

750 W High St, Ste 250, Lima, OH 45801

Open in the dashboard

General payments

$2,555

134 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Robert Wheeler of Lima, OH is reported in the CMS Open Payments database as having received $2,555 across 134 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $869 51
2021 General $616 33
2020 General $628 24
2019 General $442 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Wheeler
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Robert Wheeler were reported at $0. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Robert Wheeler Critical Care Medicine median Middle half National median
2019 $442 $149 $51–$535 $163
2020 $628 $110 $30–$325 $114
2021 $616 $125 $34–$403 $132
2022 $869 $157 $49–$582 $149
2023 $0 $162 $56–$621 $160
2024 $0 $168 $53–$634 $164
2025 $0 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Tandem Diabetes Care, Inc. $300 1 payment
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $224 12 payments
  3. Novo Nordisk Inc $146 11 payments
  4. AbbVie, Inc. $146 10 payments
  5. Indivior Inc. $139 5 payments
  6. Gilead Sciences, Inc. $136 9 payments
  7. AstraZeneca Pharmaceuticals LP $125 2 payments
  8. Janssen Pharmaceuticals, Inc $102 7 payments
  9. Novartis Pharmaceuticals Corporation $102 7 payments
  10. Merck Sharp & Dohme Corporation $96 6 payments
  11. Other $1,039 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $2,229 131 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $300 1 payment
  3. Education $26 2 payments
Products named General payments · program years 2019–2022
  1. t:slim X2 insulin pump $300 1 payment
  2. JARDIANCE $139 7 payments
  3. Ozempic $135 10 payments
  4. NURTEC ODT $127 7 payments
  5. FARXIGA $125 2 payments
  6. RYBELSUS $123 9 payments
  7. SUBLOCADE $119 4 payments
  8. MAVYRET $103 7 payments
  9. SPIRIVA RESPIMAT $103 5 payments
  10. XARELTO $102 7 payments
  11. Other $1,790 109 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

134 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record